Functional selectivity through protean and biased agonism: Who steers the ship?

Molecular Pharmacology

Volumn 72, Issue 6, 2007, Pages 1393-1401

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBACHOL; DICHLORISOPRENALINE; DRUG RECEPTOR; MUSCARINIC AGENT; OXOTREMORINE; PROPRANOLOL;

AGONIST; CHEMICAL STRUCTURE; CONFORMATION; DRUG SELECTIVITY; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 36348946976     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.040352     Document Type: Short Survey

References (51)

1. Azzi M, Charest PG, Angers S, Rousseau G, Kohout (2003) β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc Natl Acad Sci U S A 100:11406-11411.
2. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
4. Black JW and Leff P (1983) Operational models of pharmacological agonist. Proc R Soc Lond Biol 220:141-162.
5. Bockaert J and Pin JP (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary process. EMBO J 18:1723-1729.
6. Bockaert J, Dumuis A, Fagni L, and Marin P (2004) GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? Curr Opin Drug Discov Devel 7:649-657.
7. Brady AE and Limbird LE (2002) G-protein coupld receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 14:297-309.
8. Charest PG, Terrillon S, and Bouvier M (2005) Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Reports 6:334-340.
9. 2-adrenergic receptor. Mol Pharmacol 50:662-666.
10. Costa T, Klinz FJ, Vachon L, and Herz A (1988) Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. Mol Pharmacol 34:744-754.
11. 2-adrenergic receptors to two G-proteins with opposing effects. J Biol Chem 267:15795-15801.
12. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
13. Gavarini S, Becamel C, Altier C, Lory P, Poncet J, Wijnholds J, Bockaert J, and Marin P (2006) Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine(2C) receptor desensitization and membrane stability. Mol Biol Cell 17:4619-4631.
14. 2-adrenergic receptor: evidence for ligand specific conformational changes. J Biol Chem 270:28268-28275.
15. 2-adrenergic receptor. J Biol Chem 276:24433-24436.
16. Hanson SM and Gurevich VV (2006) The differential engagement of arrestin surface charges by the various functional forms of the receptor. J Biol Chem 281:3458-3462. 16339758
17. 2- adrenergic receptor and have a Phe substitute in the G-protein-activator sequence motif. FEBS Lett 311:29-32.
18. Kenakin TP (1995a) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
19. Kenakin TP (1995b) Pharmacological Proteus? Trends Pharmacol Sci 16:256-258.
20. Kenakin TP (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413-463.
21. Kenakin TP (1997) The Pharmacologic Analysis of Drug Receptor Interaction, 3rd ed, Lippincott-Raven, New York.
22. Kenakin TP (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
23. Kenakin TP (2002a) Efficacy at G protein coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
24. Kenakin TP (2002b) Efficacy at G protein coupled receptors. Nat Rev Drug Discov 1:103-110.
25. Kenakin TP (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
26. Kenakin TP (2004) Efficacy as a vector: the prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
27. Kenakin TP (2006) Collateral efficacy as pharmacological problem applied to new drug discovery. Exp Opin Drug Discov 1:635-652.
28. Kenakin TP (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28:407-415.
29. 1B-adrenergic receptor by all amino acid substitutions at a single site. J Biol Chem 267:1430-1433.
30. Laugwitz KL, Allgeier A, Offermanns S, Spicher K, Van Sande J, and (1996) The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci U S A 93:116-120.
31. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
32. Lefkowitz RJ (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 25:413-422.
33. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by β-arrestins. Science 308:512-517.
34. Lefkowitz RJ, Rajagopal K, and Whalen EJ (2006) New roles for beta-arrestins in cell signaling: not just seven-transmembrane receptors. Mol Cell 24:643-652.
35. Luttrell LM (2005) Composition and function of G protein-coupled receptor signal-somes controlling mitogen-activated protein kinase activity. J Mol Neurosci 26:253-263.
36. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, and Galzi JL (2007) A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 21:2124-2134.
37. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, and Kostenis E (2005) Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol 68:393-402.
38. i protein interactions. Mol Pharmacol 67:2016-2024.
39. Münch G, Dees C, Hekman M, and Palm D (1991) Multisite contacts involved in coupling of the β-adrenergic receptor with the stimulatory guanine-nucleotide-binding regulatory protein. Eur J Biochem 198:357-364.
40. Oppermann M, Mack M, Proudfoot AEI, and Olbrich H (1999) Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J Biol Chem 274:8875-8885.
41. Palanche T, Ilien B, Zoffmann S, Reck MP, Nucher B, Edelstein SJ et al (2001) The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 276:34853-34861.
42. Perez DM and Karnik SS (2005) Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 57:147-161.
43. Proudfoot AEI, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Scroder, J.-M, Power CA, and Wells TNC (1999) Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 274:32478-32485.
44. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, Dohlman HG et al. (2003) Identification of allosteric peptide agonists. J Biol Chem 278:896-907.
45. Spengler D, Waber C, Pantolini C, Hosboer F, Bockaert J, Seeburgt PH, and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175.
46. 2-adrenoceptor: B2 kinetic evidence for intermediate conformation states. J Biol Chem 279:686-691.
47. Terrillon S and Bouvier M (2004) Receptor activity-independent recruitment of β-arrestin reveals specific signaling modes. EMBO J 23:3950-3961.
48. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
49. Watson C, Chen G, Irving PE, Way J, Chen W-J, and Kenakin TP (2000) The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58:1230-1238.
50. Xiao K, Shenoy SK, Nobles K, and Lefkowitz RJ (2004) Activation-dependent conformational changes in β-arrestin 2. J Biol Chem 279:55744-55753.
51. 2-adrenoceptor. Nat Chem Biol 2:417-422.